

10-17-05

C8C

Please type a plus sign (+) inside this box → +

PTO/SB/21 (05-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

## TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Issued Dated	6,921,531
Issued Date	July 26, 2005
Application Number	10/025,936
Filing Date	December 21, 2001
First Named Inventor	BRIESEWITZ, ROGER
Group Art Unit	1651
Examiner Name	NAFF, DAVID M.

Total Number of Pages in This Submission

13

Attorney Docket Number

STAN-066DIV

## ENCLOSURES (check all that apply)

<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Assignment Papers (for an Application)	<input type="checkbox"/> After Allowance Communication to Group
<input checked="" type="checkbox"/> Credit Card Payment Form	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment / Reply	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input checked="" type="checkbox"/> Petition for Certificate of Correction (1 pg.)	<input checked="" type="checkbox"/> Copy of Notice of Recordation of Assignment recorded 08/15/2005 (6 pgs.)
<input type="checkbox"/> Affidavits/declaration(s)	<input checked="" type="checkbox"/> Certificate of Correction (1 pg.)	<input type="checkbox"/> Other Enclosure(s) (please identify below):
<input type="checkbox"/> Extension of Time Request	<input checked="" type="checkbox"/> Petition Under 37 C.F.R. §1.183 (1 pg.)	<input type="checkbox"/> Copy of First/Last Page of Issued Patent (2 pgs.)
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Terminal Disclaimer	<input type="checkbox"/> Postcard
<input type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> Request for Refund	
<input type="checkbox"/> Certified Copy of Priority Documents	<input type="checkbox"/> CD, Number of CD(s)	
<input type="checkbox"/> Response to Missing Parts/Incomplete Application		
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53		

Remarks

## SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Signing Attorney/Agent  
(Reg. No.)EDWARD J. BABA, 52,581  
BOZICEVIC, PIELD & FRANCIS, LLP

Signature

Date

October 14, 2005

Certificate

OCT 21 2005

of Correction

EXPRESS MAIL LABEL NO. EV 687 633 597 US

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

OCT 24 2005



EXPRESS MAIL NO.: EV 687 633 597 US

<b>PETITION UNDER 37 C.F.R. §1.183</b>  Address to: Mail Stop DAC Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450	Attorney Docket	STAN-066DIV
	First Named Inventor	BRIESEWITZ, ROGER
	Patent Number	6,921,531
	Issue Date	July 26, 2005
	Application Number	10/025,936
	Filing Date	December 21, 2001
	Title:	<i>"ADMINISTERING BIFUNCTIONAL MOLECULES CONTAINING A DRUG MOIETY AND PRESENTER PROTEIN LIGAND FOR THERAPY"</i>

Sir:

Applicants request that 37 C.F.R. 3.81(a) be waived to permit the correct name of the assignee to be provided. Applicants assert that the failure to include the correct assignee name on the PTOL-85B was inadvertent.

Upon granting of this petition, Applicants request that the accompanying petition for certificate of correction be forwarded to the Certificate of Corrections Branch.

The Commissioner is hereby authorized to charge any fees under 37 C.F.R. § 1.20, which may be required by this paper, or to credit any overpayment, to Deposit Account No. 50-0815 order number STAN-066DIV.


10/19/2005 HLE333 00000020 10025936

01 FC:1462

400.00 DP

Respectfully submitted,  
BOZICEVIC, FIELD & FRANCIS LLP

Date: October 14, 2005

By:   
Edward J. Baba  
Registration No. 52,581

BOZICEVIC, FIELD & FRANCIS LLP  
1900 University Avenue, Suite 200  
East Palo Alto, California 94303  
Telephone: (650) 327-3400  
Fax: (650) 327-3231



**PETITION FOR CERTIFICATE OF  
CORRECTION**

Address to:  
Mail Stop DAC  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Attorney Docket	STAN-066DIV
First Named Inventor	BRIESEWITZ, ROGER
Patent Number	6,921,531
Issue Date	July 26, 2005
Application Number	10/025,936
Filing Date	December 21, 2001
Title:	<i>"ADMINISTERING BIFUNCTIONAL MOLECULES CONTAINING A DRUG MOIETY AND PRESENTER PROTEIN LIGAND FOR THERAPY"</i>

Sir:

Transmitted herewith for filing is a Certificate of Correction for the above-identified patent to correct typographical errors contained within Claim 16 and the Assignee name. Please replace the Assignees names from "The Board of Trustees of the Leland Stanford Jr. University, Palo Alto, CA (US); The Howard Hughes Medical Institute, Chevy Chase, MD (US)" with --"The Board of Trustees of the Leland Stanford Jr. University, Palo Alto, CA (US)--.

Enclosed is a copy of Assignment recorded on August 15, 2005 showing that Howard Hughes Medical Institute assigned all rights to The Board of Trustees of the Leland Stanford Jr. University. Also, enclosed is a copy of the front and last page of the issued patent showing the incorrect assignees and claim 16.

Applicants attach hereto the appropriate fee of \$100.00 to cover the cost of this petition. The Commissioner is hereby authorized to charge any additional fees under 37 C.F.R. § 1.20, which may be required by this paper, or to credit any overpayment, to Deposit Account No. 50-0815 order number STAN-066DIV.


10/19/2005 HLE333 0000019 6921531

01 FC:1811

100.00 0P

Respectfully submitted,  
BOZICEVIC, FIELD & FRANCIS LLP

By:

  
Edward J. Baba  
Registration No. 52,581

BOZICEVIC, FIELD & FRANCIS LLP  
1900 University Avenue, Suite 200  
East Palo Alto, California 94303  
Telephone: (650) 327-3400  
Fax: (650) 327-3231

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.  
(Also form PTO-1050)

## UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

PATENT NO : 6,921,531

DATED : July 26, 2005

INVENTOR(S) : BRIESEWITZ, ROGER, et al.

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

On the first page of the issued patent, the Assignees "The Board of Trustees of the Leland Stanford Jr. University, Palo Alto, CA (US); The Howard Hughes Medical Institute, Chevy Chase, MD (US)" should be replaced with the assignee --**The Board of Trustees of the Leland Stanford Jr. University, Palo Alto, CA (US)**--.

In Col. 38, Claim 16, line 30, please delete the word "the"; and

In Col. 38, Claim 16, line 31, please delete the word "the".

MAILING ADDRESS OF SENDER:

BOZICEVIC, FIELD & FRANCIS LLP  
1900 University Avenue, Suite 200  
East Palo Alto, California 94303

PATENT NO. 6,921,531

No. of additional copies



Burden Hour Statement: This form is estimated to take 1.0 hour to complete. Time will vary depending upon the needs of the individual case. Any comment on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

OCT 24 2005



UNITED STATES DEPARTMENT OF COMMERCE  
Patent and Trademark Office  
ASSISTANT SECRETARY AND COMMISSIONER  
OF PATENTS AND TRADEMARKS  
Washington, D.C. 20231

\*800020210A\*

\*800020210A\*

AUGUST 15, 2005

PTAS

BOZICEVIC, FIELD & FRANCIS LLP  
1900 UNIVERSITY BLVD  
EAST PALO ALTO, CA 94303

COPY

UNITED STATES PATENT AND TRADEMARK OFFICE  
NOTICE OF RECORDATION OF ASSIGNMENT DOCUMENT

THE ENCLOSED DOCUMENT HAS BEEN RECORDED BY THE ASSIGNMENT DIVISION OF THE U.S. PATENT AND TRADEMARK OFFICE. A COMPLETE MICROFILM COPY IS AVAILABLE AT THE ASSIGNMENT SEARCH ROOM ON THE REEL AND FRAME NUMBER REFERENCED BELOW.

PLEASE REVIEW ALL INFORMATION CONTAINED ON THIS NOTICE. THE INFORMATION CONTAINED ON THIS RECORDATION NOTICE REFLECTS THE DATA PRESENT IN THE PATENT AND TRADEMARK ASSIGNMENT SYSTEM. IF YOU SHOULD FIND ANY ERRORS OR HAVE QUESTIONS CONCERNING THIS NOTICE, YOU MAY CONTACT THE EMPLOYEE WHOSE NAME APPEARS ON THIS NOTICE AT 703-308-9723. PLEASE SEND REQUEST FOR CORRECTION TO: U.S. PATENT AND TRADEMARK OFFICE, MAIL STOP: ASSIGNMENT SERVICES DIVISION, P.O. BOX 1450, ALEXANDRIA, VA 22313.

RECORDATION DATE: 08/15/2005

REEL/FRAME: 016400/0823  
NUMBER OF PAGES: 3

BRIEF: ASSIGNMENT OF ASSIGNOR'S INTEREST (SEE DOCUMENT FOR DETAILS).  
DOCKET NUMBER: STAN-066DIV

ASSIGNOR:  
HOWARD HUGHES MEDICAL INSTITUTE

DOC DATE: 09/20/1999

ASSIGNEE:  
THE BOARD OF TRUSTEES OF THE  
LELAND STANFORD JUNIOR  
UNIVERSITY  
1705 EL CAMINO REAL  
PALO ALTO, CALIFORNIA 94306-1106

SERIAL NUMBER: 10025936  
PATENT NUMBER: 6921531  
TITLE: ADMINISTERING BIFUNCTIONAL MOLECULES CONTAINING A DRUG MOIETY AND  
PRESENTER PROTEIN LIGAND FOR THERAPY

FILING DATE: 12/21/2001  
ISSUE DATE: 07/26/2005

08/29/05  
DOCKETED

OCT 24 2005

016400/0823 PAGE 2

ASSIGNMENT DIVISION  
OFFICE OF PUBLIC RECORDS

**COPY**

## PATENT ASSIGNMENT

Electronic Version v08

Stylesheet Version v02

OCT 14 2005

08/15/2005

800020210

PATENT & TRADEMARK OFFICE  
U.S. DEPARTMENT OF COMMERCE

SUBMISSION TYPE:

NEW ASSIGNMENT

NATURE OF CONVEYANCE:

ASSIGNMENT OF ASSIGNOR'S INTEREST

## CONVEYING PARTY DATA

Name	Execution Date
Howard Hughes Medical Institute	1999-09-20

COPY

## RECEIVING PARTY DATA

Name	Street Address	Internal Address	City	State/Country	Postal Code
The Board of Trustees of the Leland Stanford Junior University	1705 El Camino Real		Palo Alto	CALIFORNIA	94306- 1106

## PROPERTY NUMBERS Total: 1

Property Type	Number
Application Number	10025936

## CORRESPONDENCE DATA

FAX NUMBER: 6503273231

*Correspondence will be sent via US Mail when the fax attempt is unsuccessful.*

When the customer number has been provided, the Office of Public Records will obtain the correspondence data from the official record on file at the USPTO.

CUSTOMER NUMBER: 024353

NAME OF PERSON SIGNING:	Edward J. Baba
DATE SIGNED:	2005-08-11

Total Attachments: 2

source=Assign1.tif

source=Assign2.tif

OP \$40.00 10025936

OCT 24 2005

COPY

ASSIGNMENT	Attorney Docket Number	SUN-66P
	First Named Inventor:	Roger Briesewitz
	Title	Bifunctional Molecules..
	Filing Date	May 21, 1999
	Group Art Unit	1646
	Examiner	Unassigned

WHEREAS the Howard Hughes Medical Institute, a Delaware Corporation, ("Assignor") was assigned the rights to an invention and patent application filed thereon entitled Bifunctional Molecules and Therapies Based Thereon, for which an application for a United States Patent was filed on May 21, 1999, Application Serial no. 09/316,932; Stanford University docket number S97-144; and Howard Hughes Medical Institute reference number 022506-98-01295; and all continuation and division patent applications and Letters Patent that may issue thereon worldwide (the "Invention"); and

WHEREAS, Assignor has agreed to transfer to The Board of Trustees of Leland Stanford Junior University, a non-profit educational institution of the State of California ("Assignee") all of Assignor's interest in, to and under such patent application and all continuation and division applications and Letters Patent that may issue thereto (including foreign counterparts thereto); and


NOW THEREFORE, for good and valuable consideration, the receipt of which is hereby acknowledged, Assignor hereby sells, assigns and transfers to Assignee full and exclusive right, title and interest to the invention, Letters Patent that may issue thereon, and any continuation, division, extension, renewal, substitution, reissue, reexamined patent or foreign counterpart thereof for the full term or terms for which the same was granted.

Assignor hereby covenants that no assignment, sale or agreement transfer or encumbrance has been or will be made or entered into which would conflict with this assignment or sale.

Assignor further covenants that Assignee will, upon its request, be provided promptly with all pertinent facts and documents relating to said invention, said applications and said Letters Patent (including any continuation applications, divisional applications, foreign counterparts and patents issuing thereon), as may be known and accessible to Assignor and will testify regarding the same in any interference or litigation related thereto and will promptly execute and deliver to Assignee or its legal representative any and all papers, instruments or affidavits required to apply for, obtain, maintain, and enforce rights in, to and under said invention, said application, and said Letters Patent which may be necessary or desirable, without further compensation, but at the expense of Assignee, its successors, assigns or other legal representatives.

20  
EXECUTED this 20 th day of September 1999

ASSIGNOR  
Howard Hughes Medical Institute

By:   
Gerald R. Crabtree

for myself and as an Agent of the Howard Hughes Medical Institution

597-144 C  
HHMI 1295

APPOINTMENT OF INVESTIGATOR AS AGENT

**COPY**

Appointment by the Howard Hughes Medical Institute (the "Institute") of Dr. Gerald R. Crabtree, an investigator employed by the Institute, as its agent for the purpose of assigning certain rights to The Board of Trustees of the Leland Stanford Junior University (the "University").

WHEREAS, the Institute and the University collaborate in the active conduct of medical research pursuant to a Patent and Intellectual Property Agreement between them dated as of January 1, 1985 (the "Agreement");

WHEREAS, pursuant to the Agreement, the Institute has agreed to assign to the University the Institute's rights with respect to inventions, discoveries, improvements, and other intellectual property, whether patentable or copyrightable (each a "Subject Property"), conceived or reduced to practice in the course of the research program conducted under the Agreement by employees of the Institute;

WHEREAS, research conducted pursuant to the Agreement by Dr. Crabtree while employed by the Institute at the University has resulted in the invention of a certain Subject Property entitled "Enhancement of Drug-Target Affinities by Protein Based Enlargement of the Drug Surface," which may be the subject of a patent application (the "Invention"), and the Invention is a Subject Property; and

WHEREAS, the Institute wishes Dr. Crabtree to act as its agent for the purpose of assigning to the University the rights the Institute has in the Invention by reason of the research program conducted at the University,

NOW, THEREFORE, the Institute hereby appoints Dr. Crabtree as its agent for the purpose of assigning the rights the Institute has in the Invention by reason of the research program conducted at the University to the University in accordance with and subject to the conditions of the Agreement.

Executed July 14, 1998

HOWARD HUGHES MEDICAL INSTITUTE

By: W. Maxwell Cowan

W. Maxwell Cowan, M.D., Ph.D.

Vice President and Chief Scientific Officer

ATTESTED:

John S. Leonard  
John S. Leonard, Esq.

Vice President and General Counsel and Secretary

S97-144  
HHMI 022506-98-01295

OCT 24 2005

# Facsimile Transmission

**RECEIVED**

*This company uses RightFAX® fax server software from RightFAX, Inc.*

AUG 15 2005

Bozicevic, Field, &amp; Francis

From: Name: USPTO ASSIGNMENT DIVISION  
Fax Number:  
Voice Phone: 703-308-9723

**ORIGINAL to: PJS**  
**COPIES to: EJB MAC**

To: Name: SUBMITTER  
Company: Faxed to Submitter's Fax Number  
Fax Number: 16503273231  
Voice Phone:

**COPY****Fax Notes:**STAN OGD DIV**Pg# Description**

- 1 Cover Page
- 2 239.TXT
- 4 Document 1, Batch 512214

PTAS FAX PROCESSING

---

Date and time of transmission: Monday, August 15, 2005 3:31:46 PM  
Number of pages including this cover sheet: 04

*A RightFAX® Communicated Document*

OCT 24 2005



US006921531B2

(12) **United States Patent**  
Briesewitz et al.

(10) **Patent No.:** US 6,921,531 B2  
(45) **Date of Patent:** Jul. 26, 2005

(54) **ADMINISTERING BIFUNCTIONAL MOLECULES CONTAINING A DRUG MOIETY AND PRESENTER PROTEIN LIGAND FOR THERAPY**

(75) Inventors: **Roger Briesewitz**, Mountain View, CA (US); **Gerald R. Crabtree**, Woodside, CA (US); **Thomas Wandless**, Menlo Park, CA (US); **Gregory Thomas Ray**, Stanford, CA (US); **Kurt William Vogel**, Palo Alto, CA (US)

(73) Assignees: **The Board of Trustees of the Leland Stanford Junior University**, Palo Alto, CA (US); **Howard Hughes Medical Institute**, Chevy Chase, MD (US)

(\*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 88 days.

(21) Appl. No.: 10/025,936

(22) Filed: Dec. 21, 2001

(65) **Prior Publication Data**

US 2002/0147133 A1 Oct. 10, 2002

**Related U.S. Application Data**

(62) Division of application No. 09/316,932, filed on May 21, 1999, now Pat. No. 6,372,712.

(60) Provisional application No. 60/086,451, filed on May 22, 1998.

(51) **Int. Cl.** 7 ..... A61K 38/52; A61K 38/00; C12N 11/02; C07K 1/00; C07K 17/02

(52) **U.S. Cl.** ..... 424/94.5; 424/94.1; 514/2; 514/9; 435/177; 530/402; 530/812

(58) **Field of Search** ..... 514/2, 9; 424/94.1, 424/94.5; 435/177; 530/402, 812

(56) **References Cited**

**U.S. PATENT DOCUMENTS**

5,382,657 A	1/1995	Karasiewicz et al.
5,830,462 A	11/1998	Crabtree et al. .... 424/93.21
5,834,266 A	11/1998	Crabtree et al. .... 435/172.3
5,840,733 A	11/1998	Krantz et al. .... 514/311
5,843,440 A	12/1998	Pouletty et al. .... 424/133.1
5,869,337 A	2/1999	Crabtree et al. .... 435/372.3
5,871,753 A	2/1999	Crabtree et al. .... 424/280.1
6,670,348 B1	12/2003	Rosen et al. .... 514/174
2002/0045570 A1	4/2002	Rosen et al. .... 514/2

**FOREIGN PATENT DOCUMENTS**

WO	91/01743	2/1991
WO	94/18317	8/1994
WO	95/02684	1/1995
WO	95/05389	2/1995
WO	95/10302	4/1995
WO	96/06111	2/1996
WO	96/12796	5/1996
WO	97/25074	7/1997
WO	97/29372	8/1997
WO	98/00171	1/1998

WO 98/11437 3/1998  
WO 98/46270 10/1998  
WO 98/47916 10/1998

**OTHER PUBLICATIONS**

Atwell, John L., et al., "Design and Expression of a Stable Bispecific scFv Dimer With Affinity for Both Glycophorin and N9 Neuraminidase," *Molecular Immunology* (1996) vol. 22, No. (17/18):1301-1302.

Bernstein, Kenneth E., et al., "A Deeply Recessed Active Site in Angiotensin-Converting Enzyme Is Indicated From the Binding Characteristics of Biotin-Spacer-Inhibitor Reagents," *Biochemical and Biophysical Communications* (Feb. 28, 1990) vol. 167, No. (1):310-316.

Bourdouxhe-Honsiaux, Catherine, et al., "Interaction of DNA-Threading Peptide-Amsacrine Conjugates With DNA and Chromatin," *Anti-Cancer Drug Design* (1996) vol. 11:509-525.

Chakraborty, TK., et al., "Design and Synthesis of a Rapamycin-Based High Affinity Binding FKBP12 Ligand," *Chemistry & Biology* (Mar. 1995) vol. 2:157-161.

Crabtree, Gerald R., et al., "Three-Part Inventions: Intracellular Signalling and Induced Proximity," *Elsevier Trends Journal* (Nov. 1996) pp:418-422.

Ho, Steffan N., et al., "Dimeric Ligands Define a Role for Transcriptional Activation Domains In Reinitiation," *Nature* (Aug. 29, 1996) vol. 382, No. (6594):822-826.

Kramer, Werner, et al., "Liver-Specific Drug Targeting by Coupling to Bile Acids," *The Journal of Biological Chemistry* (1992) vol. 267, No. (2): 18598-18604.

Mogre, R.M., et al., "A New Carbene Based Heterobifunctional Reagent: Photochemical Crosslinking of Aldolase," *FEBS Letters* (Sep. 1987) vol. 221, No. (2):408-414.

Mu, Yu., et al., "Biconjugation of Laminin Peptide YIGSR With Poly(Styrene Co-Maleic Acid) Increases Its Antimetastatic Effect on Lung Metastasis of BI6-BL6 Melanoma Cells," *Biochemical and Biophysical Research Communications* (1999) vol. 255:75-79.

Varshavsky, Alexander, "Codominant Interference, Antifection, and Multitarget Drugs," *Proc. Natl. Acad. Sci. USA* (Mar. 1998) vol. 95:2094-2099.

(Continued)

**Primary Examiner**—David M. Naff

**(74) Attorney, Agent, or Firm**—Bret E. Field; Bozicevic, Field & Francis LLP

(57) **ABSTRACT**

Bifunctional molecules and methods for their use in the production of binary or tripartite complexes in a host are provided. The bifunctional molecule is a conjugate of a drug moiety and a presenter protein ligand. The molecular weight of the bifunctional molecule is less than about 5000 daltons. In the methods, an effective amount of the bifunctional molecule is administered to the host. In certain embodiments the bifunctional molecule binds to the presenter protein and a drug target to produce a tripartite complex, while in other embodiments the bifunctional molecule binds to either the presenter protein or the drug target, but not both, to produce a binary complex. The subject methods and compositions find use in a variety of therapeutic applications.

cultures is inhibited in a concentration dependent fashion. When these cells are transformed with a vector that allows the inducible expression of human FKBP, the bacteria become less sensitive to the bifunctional molecule when FKBP is expressed. To demonstrate that this detoxification of the bifunctional molecule is based on binding to FKBP, increasing concentrations of FK506 are added to the culture medium. FK506 competes with the bifunctional molecule for FKBP binding so that increasing concentrations of free bifunctional molecule are present which can inhibit DHFR. FK506 by itself has no effect on the growth of the bacterial cultures in the presence or absence of FKBP.

This assay demonstrates that the presence of FKBP protects cells from the DHFR inhibitory activity of pteridine-FKBP ligand bifunctional molecules. This observation is the basis for creating cell selective anti-microbials that show reduced toxicity in humans.

It is evident from the above results and discussion that the subject invention provides a powerful tool for improving the affinity and/or specificity and selectivity of drugs. As such, the subject method provides for the improvement of drugs currently in use, e.g. by reducing unwanted side effects. Furthermore, the subject methods can be used to improve drugs that have, until now, been clinically useless due to considerable toxicity in humans and animals. Therefore, the invention provides for the potential usefulness of the variety of previously discovered and discarded biologically active compounds. Accordingly, the invention provides an important advancement in pharmacological science.

All publications and patent applications cited in this specification are herein incorporated by reference as if each individual publication or patent application were specifically and individually indicated to be incorporated by reference. The citation of any publication is for its disclosure prior to the filing date and should not be construed as an admission that the present invention is not entitled to antedate such publication by virtue of prior invention.

Although the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, it is readily apparent to those of ordinary skill in the art in light of the teachings of this invention that certain changes and modifications may be made thereto without departing from the spirit or scope of the appended claims.

What is claimed is:

1. In a method of administering a drug to a host in need of said drug, the improvement comprising:

administering to said host an effective amount of a bifunctional molecule of less than about 5000 daltons consisting of said drug or a fragment thereof linked to a ligand for a presenter protein endogenous to said host, wherein said drug binds to a drug target and said ligand binds to a presenter protein that is not said drug target.

2. The method according to claim 1, wherein said host is a mammalian host.

3. The method according to claim 2, wherein said mammalian host is human.

4. The method according to claim 1, wherein said drug is a small molecule.

5. The method according to claim 1, wherein said drug binds to an extracellular target.

6. The method according to claim 1, wherein said drug binds to an intracellular target.

7. The method according to claim 6, wherein said presenter protein ligand is a peptidyl prolyl isomerase.

8. The method according to claim 1, wherein said drug moiety and ligand of said bifunctional molecule are joined by a linking group.

9. A method for producing a tripartite complex in a mammalian host, said method comprising:

administering to said mammalian host an effective amount of a bifunctional molecule of less than about

5000 daltons consisting of a drug moiety linked to a ligand for a presenter protein endogenous to said mammalian host, wherein said drug moiety binds to a drug target and said ligand binds to a presenter protein that is not said drug target to produce said tripartite complex of said drug target, bifunctional molecule and presenter protein in said mammalian host.

10. The method according to claim 9, wherein said tripartite complex is produced intracellularly.

11. The method according to claim 9, wherein said tripartite complex is produced extracellularly.

12. The method according to claim 9, wherein said drug target is a protein.

13. The method according to claim 9, wherein said endogenous presenter protein is selected from the group consisting of: peptidyl-prolyl isomerasers, Hsp90, steroid hormone receptors, cytoskeletal proteins, albumin and vitamin receptors.

14. The method according to claim 9, wherein said bifunctional molecule is administered as a pharmaceutical preparation.

15. The method according to claim 9, wherein said drug moiety and ligand of said bifunctional molecule are joined by a linking group.

16. A method for producing an intracellular tripartite complex in a mammalian host, said method comprising:

30 administering to said mammalian host an effective amount of a bifunctional molecule of less than about 5000 daltons comprising a drug moiety linked to a endogenous presenter protein ligand, wherein the said drug moiety and the said endogenous presenter protein ligand bind to different intracellular proteins; to produce said intracellular tripartite complex.

17. The method according to claim 16, wherein said endogenous presenter protein is selected from the group consisting of: peptidyl prolyl isomerasers, Hsp90, steroid hormone receptors and cytoskeletal proteins.

18. The method according to claim 17, wherein said endogenous presenter protein is a peptidyl prolyl isomerase.

19. The method according to claim 16, wherein said drug moiety and ligand of said bifunctional molecule are joined by a linking group.

20. A method for enhancing the selectivity of a drug for an intracellular drug target in a first cell as compared to a second cell, containing the drug target said method comprising:

35 contacting said first and second cells with a bifunctional molecule of less than about 5000 daltons comprising said drug linked to a ligand for a presenter protein that is not said drug target present in said second cell but not in said first cell, wherein said drug binds to the drug target in said first cell and said ligand binds to the presenter protein in said second cell;

40 to produce a binary complex comprising said bifunctional molecule and presenter protein in said second cell wherein the drug does not bind to the drug target in the second cell, and to produce a binary complex comprising said bifunctional molecule and drug target in said first cell wherein the drug binds to the drug target in the first cell.

21. The method according to claim 20, wherein said drug is an antimicrobial agent.

22. The method according to claim 20, wherein said ligand is a peptidyl prolyl isomerase ligand.

23. The method according to claim 20, wherein said drug moiety and ligand of said bifunctional molecule are joined by a linking group.

\* \* \* \* \*